<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82389">
  <stage>Registered</stage>
  <submitdate>2/11/2007</submitdate>
  <approvaldate>6/11/2007</approvaldate>
  <actrnumber>ACTRN12607000571471</actrnumber>
  <trial_identification>
    <studytitle>A Pilot Study - Ziprasidone used as an Adjunctive Therapy in patients with Major Depressive Disorder: Impact on Symptoms and Functional Disability</studytitle>
    <scientifictitle>A Pilot Study - Ziprasidone used as an Adjunctive Therapy in patients with Major Depressive Disorder: Impact on Symptoms and Functional Disability</scientifictitle>
    <utrn />
    <trialacronym>Ziprasidone in Major Depression</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Major Depressive Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The starting dose of 20mg oral Ziprasidone hydrochloride daily, will be gradually increased up to the maximum daily dose of 80mg for 3 weeks. During this time, the daily dose will be increased or decreased as required, based on the subjects tolerability. Once established, the subject will remain on this stable dose for the remaining 3 weeks of the study.</interventions>
    <comparator>Uncontrolled; single group trial</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>A &gt; 20% change in score on the Hamilton Depression Rating Scale (HAMD-17), from baseline to week 6.</outcome>
      <timepoint>At baseline, and at 2,4 and 6 weeks after intervention commencement.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>A reduction in the Clinical Global Impression Scale (CGI) score by at least 1 point, from baseline to week 6.</outcome>
      <timepoint>At baseline, and at 2,4 and 6 weeks after intervention commencement.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>N/A</outcome>
      <timepoint>N/A</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patients with a diagnosis of Major Depressive Disorder (MDD) as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria
2. Aged 18 to 55 years old
3. A history during the current depressive episode of an incomplete or partial response to a trial of a selective serotonin reuptake inhibitors antidepressant (SSRIs), or a noradrenergic and specific serotonergic antidepressant (NASSA), at an adequate dose for a minimum of 6 weeks.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Pregnancy
2. Lactation
3. Severe or unstable medical condition
5. Co-morbid diagnosis of any primary psychotic disorder or Personality Disorder
6. Co-morbid diagnosis of alcohol/substance abuse
7. Unable to obtain written informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>15/01/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3144</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Nitin Dharwadkar</primarysponsorname>
    <primarysponsoraddress>The Melbourne Clinic
12/140 Church St
Richmond
VIC
3121</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer Global Pharmaceuticals</fundingname>
      <fundingaddress>Pfizer Clinical Research
38-42 Wharf Road
West Ryde
NSW
2114</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Victorian Psychopharmacology Research Group</sponsorname>
      <sponsoraddress>290 Glenferrie Road 
Malvern
VIC
3144</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is a 6-week, naturalistic open-label evaluation of the efficacy and tolerability of ziprasidone hydrochloride (20mg/day to 80mg/day), in combination with an antidepressant in the treatment of patients with major depressive disorder (MDD), and aims to assess the antidepressant effect of ziprasidone in conjunction with an antidepressant in treating patients who have shown an incomplete or partial response an antidepressant alone.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Cabrini Human Research Ethics Committee</ethicname>
      <ethicaddress>Cabrini Clinical Education and Research Institute
183 Wattletree Road
Malvern
3144</ethicaddress>
      <ethicapprovaldate>30/01/2008</ethicapprovaldate>
      <hrec>02-10-12-07</hrec>
      <ethicsubmitdate>22/11/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Nitin Dharwadkar</name>
      <address>The Melbourne Clinic
12/140 Church St
Richmond
VIC
3121</address>
      <phone>+61 3 9090 7789</phone>
      <fax>+61 3 9886 7093</fax>
      <email>dharwadkar@optusnet.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Nitin Dharwadkar</name>
      <address>The Melbourne Clinic
12/140 Church St
Richmond
VIC
3121</address>
      <phone>+61 3 9090 7789</phone>
      <fax>+61 3 9886 7093</fax>
      <email>dharwadkar@optusnet.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Bodil Hook</name>
      <address>290 Glenferrie Road
Malvern
VIC
3144</address>
      <phone>+61 3 9822 5033</phone>
      <fax>+61 3 9822 5055</fax>
      <email>bodil@ntvic.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>